^
    Back
    Association details:
    Biomarker:NPM1 mutation
    Cancer:Acute Myelogenous Leukemia
    Regimen: (cytarabine + fludarabine IV + idarubicin hydrochloride)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancers (Basel)
    Title:

    Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden

    Published date:
    12/24/2020
    Excerpt:
    Here, we investigated the efficacy of a fludarabine, high-dose cytarabine and idarubicin induction (FLAI) in 149 consecutive fit AML patients (median age 52) carrying the NPM1... Our data indicate that FLAI exerts a strong anti-leukemic effect in younger AML patients with NPM1mut...
    DOI:
    10.3390/cancers13010034